Research and development expenses increased by $1,506,552, or 237%, to $2,143,353 for the year ended December 31, 2024, compared to $636,801 for the year ended December 31, 2023. The increase resulted ...
This milestone approval, coming after an intensive regulatory review, marks a turning point in Chaince Securities' evolution. It strengthens the firm's position as a trusted broker-dealer that puts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback